🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

2nd GLOW summit was a resounding success thanks to Monica Palese and all GLOW members and collaborators. The thousands of patients with NLPHL diagnosed yearly deserve new therapeutic approaches GLOW: Global nLPHL One Working Group Jamie Flerlage Sharon M. Castellino Ajay Major, MD, MBA Kara Kelly

On the weekend, I had the opportunity to tell my fellow Nodular Lymphocyte Predominant Hodgkin Lymphoma enthusiasts about the great work of Lymphoma and Related Diseases Registry. Thanks Jamie Flerlage Michael Sargent Binkley #GLOW #Cologne #ISHL13 @DrElizaHawkes

🙌🙌 It was GREAT to connect w/ colleagues in the basement of the Gurzenich Köln at #ISHL13 for a #HoLISTIC consortium group meeting (hodgkinconsortium.com). 🌎🌍🌏 We are v. thankful for the incredible GLOBAL collaboration. We completed DUAs w/ nearly 20 national &

Stem cell transplants are amazing. A patient's diseased blood is replaced by a relative or stranger's. But what does putting a blood system into a new body do to the cells? How many survive? Does it matter? Out in nature today, we asked some basic Qs 👇 rdcu.be/dYCoZ

Fantastic work by Dr. Butler et al. investigating incidence of afib after XRT finding risk is highest with increasing dose to pulmonary veins. Next steps to incorporate genetic risk with these factors. Hyunsoo Joshua No, MD, CMD Bill Loo MD PhD ⚡️☢️ Max Diehn, MD/PhD JACC Journals sciencedirect.com/science/articl…

Ajay Major, MD, MBA Daniel Molin David Russler-Germain, MD/PhD Chan Cheah Haematologica GLOW: Global nLPHL One Working Group Michael Sargent Binkley Jamie Flerlage I’m not a great fan of R mono. Some activity sure, but it doesn’t last long. So in practise if I treat I would combine with gentle chemo.

When someone in the Q&A start their question with "Maybe I missed it" you know there's going to be trouble

Number 8 #LeonardList #ASH24 top #lymphoma abstract 565 – Boegeholz – ctDNA status C3D1 in rx (& later) in pts w/Hodgkin #lymphoma correlates w/outcome – may be useful tool to evaluate in risk adapted study of escalation/de-escalation of therapy in HL ash.confex.com/ash/2024/webpr…

Honorable mention #MajorPROsASH: splenic RT before allo MF Michael Sargent Binkley - 10 pts, symptomatic splenomegaly➡️MPN-SAF TSS PRO - D+90 post allo: sx splenomegaly better by 20 pts (MID is ~1.5-2 points) Phenomenal example of PRO integration into early-phase trials. #ASH24 #mpnsm

A big thank you to our collaborators (Anusha Kalbasi, Michael Sargent Binkley, among others) and funding from National Comprehensive Cancer Network (NCCN) Foundation, My Blue Dots, and the Tad and Diane Taube Family Foundation for making this project possible.

Received an unscheduled P2Peer last sunday morning at 7 am from a generic number after waiting 3 wks for 20y w brain mets. Voicemail left without name or callback. Only option is appeal now? Rather than investing in people UnitedHealthcare and optum hide without ability for a real P2P.

Our CU Lymphoma Program junior faculty Dr. Ajay Major, MD, MBA conducted a qualitative study on NLPHL perspectives from patients and their care partners, now published. cc GLOW: Global nLPHL One Working Group #lymsm tandfonline.com/doi/full/10.10…

Our GLOW: Global nLPHL One Working Group research roadmap for NLPHL is now published. In this manuscript, we review the historical research challenges in NLPHL research and progress to date of our international GLOW Consortium (glowconsortium.org). #lymsm #nlphlsm onlinelibrary.wiley.com/doi/epdf/10.10…

Grateful to have the opportunity to write this editorial on current management of classic Hodgkin lymphoma with Dr. Ranjana Advani dailynews.ascopubs.org/do/upfront-tre…

Had an amazing time at Amer. Radium Society this weekend, including sharing our work on bridging RT with Michael Sargent Binkley. Such a great conference full of leaders in our field who choose to intentionally invest in trainees.

Read the editorial written about our GLOW: Global nLPHL One Working Group research roadmap manuscript in Pediatric Blood & Cancer: onlinelibrary.wiley.com/doi/10.1002/pb… #lymsm #nlphlsm

Wonderful to see the LP-IPS score mentioned in the #18ICML NLPHL session! Congratulations to Michael Sargent Binkley Jamie Flerlage and everyone at GLOW: Global nLPHL One Working Group. Paper from Journal of Clinical Oncology is here: ascopubs.org/doi/abs/10.120… #lymsm

Congratulations to Dr. Jamie Flerlage on her oral presentation at #18ICML on our GLOW: Global nLPHL One Working Group analysis of radiotherapy in Stage IA NLPHL. #lymsm

Understanding the intricate interactions between tumors and the immune system is crucial for developing safe and effective treatments. Read about this research in an update from the Binkley Lab in our department: linkedin.com/pulse/explorin…

Our GLOW: Global nLPHL One Working Group lead Dr. Jamie Flerlage spoke about the GLOW multicenter study of radiation therapy outcomes for Stage IA NLPHL which she presented at #18ICML for VJHemOnc. #lymsm #NLPHLsm vjhemonc.com/video/amtyhj8p…